ChromaDex Corp (CDXC)

3.97
0.01 0.25
OTC : Health Care
Prev Close 3.96
Open 3.99
Day Low/High 3.97 / 4.00
52 Wk Low/High 2.46 / 6.18
Volume 21.10K
Avg Volume 470.50K
Exchange OTC
Shares Outstanding 36.55M
Market Cap 145.12M
EPS -0.10
P/E Ratio N/A
Div & Yield N.A. (N.A)

ChromaDex Clinical Trial Studying NIAGEN® Well Underway, With Eight Additional Collaborative Human Studies Active

Study results will help to define the effective dose range of nicotinamide riboside (NR) in humans when taken daily, over eight weeks.

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces The Commencement Of An Investigation Into Possible Securities Fraud Violations By Certain Officers And Directors Of ChromaDex Corporation

Levi & Korsinsky announces it has commenced an investigation of ChromaDex Corporation ("ChromaDex" or the "Company") (NASDAQ:CDXC) concerning possible violations of federal securities laws.

ChromaDex (CDXC) Is Strong On High Volume Today

Trade-Ideas LLC identified ChromaDex (CDXC) as a strong on high relative volume candidate

EQUITY ALERT: Rosen Law Firm Announces Investigation Of Securities Claims Against ChromaDex Corporation

Rosen Law Firm, a global investor rights law firm, announces it is investigating potential securities claims on behalf of shareholders of ChromaDex Corporation (NASDAQ:CDXC) resulting from allegations that ChromaDex may...

Market Digging Metal and Mining Stocks

There is some good speculative trading and metals are the place to be.

University Researchers Show Vitamin Nicotinamide Riboside Is An Effective Tool For Managing The Negative Effects Of Obesity And Diabetes

New published study shows a unique form of vitamin B3, nicotinamide riboside, may help with weight gain and glycemic control as well as protect nerves from diabetic damage

ChromaDex To Report First Quarter 2016 Financial Results On Thursday, May 12, 2016

Company Will Host Investor Conference Call on Monday, May 16, 2016

Thorne Research Announces Clinical Study To Assess Nicotinamide Riboside On Brain NAD+ In College Football Players

- Mayo Clinic, University of Minnesota and ChromaDex to Collaborate on Study -

ChromaDex To Report Year End 2015 Financial Results On Thursday, March 17, 2016

Company Will Host Investor Conference Call on Monday, March 21, 2016